-
Commercializing Gene Therapy in 2025
-
Commercializing Gene Therapy in 2025
-
Gene Therapy CMC & Process Development
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
-
Commercializing Gene Therapy in 2025
-
Gene Therapy CMC & Process Development
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
-
Commercializing Gene Therapy in 2025
-
Gene Therapy CMC & Process Development
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
-
Commercializing Gene Therapy in 2025
-
Gene Therapy CMC & Process Development
-
Gene Therapy CMC & Process Development
-
Next Gen Vector Engineering & Delivery
-
Next Gen Vector Engineering & Delivery
Optimizing tissue tropism, transduction efficiency, and cell-type specificity to lower dosing requir
...
-
Next Gen Vector Engineering & Delivery
-
Next Gen Vector Engineering & Delivery
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Autologous Therapies in Solid Tumors and Beyond
-
Autologous Therapies in Solid Tumors and Beyond
Commercial Lessons from the Front Line: Real-world insights from autologous therapy launches to refi
...
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Allogeneic Access: Engineering the Future of Cell Therapy
Key differences in process design, scalability, and consistency between T cell and NK cell platforms
...
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Allogeneic Access: Engineering the Future of Cell Therapy
Exploring lessons from OmnImmune®’s transition from fresh to cryopreserved gamma-delta T cells in re
...
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
Assay design must reflect γδ T cell-specific mechanisms of action (e.g., cytotoxicity, cytokine rele
...
-
Next Gen Vector Engineering & Delivery
-
Next Gen Vector Engineering & Delivery
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
Afternoon Refreshments
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
Morning Refreshments
-
Next Gen Vector Engineering & Delivery
-
Next Gen Vector Engineering & Delivery
Engineering capsids with enhanced tissue specificity, immune evasion, and payload capacity. Explorin
...
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
Evening Drinks Reception
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Autologous Therapies in Solid Tumors and Beyond
-
Autologous Therapies in Solid Tumors and Beyond
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
1-2-1 Meetings / Networking Break
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
1-2-1 Meetings / Networking Break
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
Networking Lunch
-
Autologous Therapies in Solid Tumors and Beyond
-
Autologous Therapies in Solid Tumors and Beyond
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
1-2-1 Meetings / Networking Break
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
1-2-1 Meetings / Networking Break
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
Streamlining upstream and downstream workflows to support consistent and scalable autologous product
...
-
Autologous Therapies in Solid Tumors and Beyond
-
Autologous Therapies in Solid Tumors and Beyond
Proprietary tools enhancing potency, precision, and control in autologous cell therapies. Manufactur
...
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
-
-
Autologous Therapies in Solid Tumors and Beyond
-
Allogeneic Access: Engineering the Future of Cell Therapy
-
Cell Therapy Manufacturing: Automation, Assays & the Allo-Auto Divide
-
Next Gen Vector Engineering & Delivery
-
Gene Therapy CMC & Process Development
-
Commercializing Gene Therapy in 2025
Registration